-
Mashup Score: 4Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial - 7 hour(s) ago
Nature Communications – Depth of response (CR/VGPR, MRD-) links to better outcomes, while biochemical progression predicts end-organ damage. Higher MHC-I on tumors and greater GZMB+ T cells…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3SUMMARY - CancerNetwork® Face-Off: MM and CML - 2 year(s) ago
Malin Hultcrantz, MD, PhDAssistant Attending PhysicianAssistant ProfessorMyeloma ServiceMemorial Sloan Kettering Cancer CenterNew York, NYMichael J. Mauro, MDLeader, Myeloproliferative Neoplasms ProgramAttending Physician, Leukemia ServiceMember, Memorial Sloan Kettering Cancer CenterProfessor of Medicine, Weill Cornell Medical CollegeNew York, NYOmar Nadeem, MD Clinical Director, Myeloma Immune…
Source: web.cvent.comCategories: Hem/Oncs, Latest HeadlinesTweet-
As NY celebrates Aaron Judge’s 61st home run, the bigger NY/BOS matchup is tonight with @MSKCancerCenter and @DanaFarber going head to head discussing all the hot topics in MM and CML! Register now! https://t.co/lMX90ImXdU #mmsm @CliftonCraigMo @ShoMidha @szusmani https://t.co/Lfl0SBB3Xr
-
-
Mashup Score: 2International Myeloma Society (IMS) Novel Immune Therapies Educational Workshop | March 18, 2022 - 3 year(s) ago
IMS Novel Immune Therapies Educational Workshop Series
Source: www.eventcreate.comCategories: Hem/Oncs, Latest HeadlinesTweet-
New England colleagues.. come join us for an exciting Friday evening IMS educational workshop on novel immune therapies in MM! @Myeloma_Society @DanaFarber @NoopurRajeMD #mmsm https://t.co/8NMFSshAaH
-
-
Mashup Score: 3Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma - Full Text View - ClinicalTrials.gov - 4 year(s) ago
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Metformin for low-risk smoldering myeloma or high-risk MGUS now open for accrual @DanaFarber @cpopclinic @IreneGhobrial #mmsm #preventprogression #curemyeloma https://t.co/1tlsm6gGme
-
-
Mashup Score: 1SUMMARY - OncLive/Institutional Perspectives in Cancer/Multiple Myeloma/May 20, 2021/ET - 4 year(s) ago
Institutional Perspectives in Cancer: Multiple Myeloma May 20, 20216:30 PM-8:00 PMETOur Institutional Perspectives in Cancer (IPC) are short meetings designed to educate oncologists and HCPs on the clinical benefits associated with the new science driving new thinking in cancer management. Our renowned faculty focus on the most relevant cancer topics to ultimately improve patient…
Source: event.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to chairing the @Onclive Multiple Myeloma IPC on 5/20 at 630pm ET. Discussion topics NDMM, RRMM, CAR T-Cell therapy, AL Amyloidosis. @OncLiveSOSS #oncliveIPC #mmsm @danafarber @adamssperling @CliftonCraigMo Giada Bianchi Register Here https://t.co/EhaP0h3YPu
-
-
Mashup Score: 4DARA RVD For High Risk SMM - Full Text View - ClinicalTrials.gov - 4 year(s) ago
DARA RVD For High Risk SMM – Full Text View.
Source: www.clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Our phase II trial B-PRISM (Precision Intervention Smoldering Myeloma) of Daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-RVD) in high-risk smoldering myeloma is now open for accrual! https://t.co/ldJnPzZutw @IreneGhobrial #mmsm
-
-
Mashup Score: 1
Hematology / Oncology News
Categories: Hem/Oncs, Latest HeadlinesTweet-
Finally!! 👏🏽🙏🏽 #mmsm https://t.co/b4BdseJFDD
-
-
Mashup Score: 28
By Nicholas Haradhvala, Oksana Zavidij, and Tarek Mouhieddine
Source: Nature Research Cancer CommunityCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @IreneGhobrial: OUR PAPER IS OUT! Early precursors of Multiple Myeloma display signs of immune compromise https://t.co/nTzJ1eFVqW #mmsm
-
Our I-PRISM trial of Ixa/Len/Dex in HR-SMM demonstrates that depth of response predicts better outcomes in HR-SMM. Pts with CR and MRD neg disease had lower risk of SLIM-CRAB and biochemical PD. @IrenemGhobrial Michelle Aranha @DanaFarber https://t.co/ixD50AwfNk